摘要
目的观察高聚生联合顺铂治疗恶性胸腔积液的临床疗效。方法将48例恶性胸水患者随机分为观察组28例和对照组20例。两组患者在胸腔闭式引流放尽胸水后观察组注入顺铂和高聚生,对照组只注入顺铂治疗。结果观察组完全有效(CR)16例,部分有效(PR)9例,总有效率89%,对照组CR4例,PR6例,总有效率50%,两组比较差异有显著性(P<0.01)。结论高聚生是一种新型的生物免疫调节剂,高聚生联合顺铂治疗恶性胸腔积液有更加确切良好的临床疗效。高聚生能够改善患者的免疫功能,协同胸腔内化疗的使用,能减轻患者因化疗药物的反应及白细胞减少,明显改善患者的生活质量。
[Objective] To observe the effects of highly agglutinative staphylococcin （HASL） combined with cisplatin （DDP） in the treatment of malignant hydrothorax. [Methods] Forty-eight patients with malignant hydrothorax were randomly divided into the therapeutic group （HASL＋DDP, 28 patients） and the control group （DDP only, 20 patients）. After completely depleting malignant pleural effusion,the therapeutic group patients were slowly injected with HASL 2 000u＋ cisplatin 100 mg into the thoracic cavity and the control group were injected cisplatin 100 mg only. [Result] The response rate of the therapeutic group was 89% （25/28） and the control group was 50% （10/20）; P〈0.01. [Conclusion] HASL is a new type of biological response modifier, which can produce an added effect as used in combination with chemotherapy. It stimulates patient immunity and releases the side effects caused by the decreased court of leucoctye. When HASL combined with cisplatin to treat malignant hydrothorax, it has a definite and curative effect with slight side effects.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2006年第3期410-412,共3页
China Journal of Modern Medicine
关键词
胸腔积液
高聚生
顺铂
胸腔内化疗
highly agglutinative staphylococcin （HASL）
cisplatin
hydrothorax
作者简介
潘友民，Email：panyoumin@126．com
